PFKFB3 and colorectal cancer: The inhibition of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) enhanced the sensitivity of NSCLCs to erlotinib by decreasing autophagy [129], and inhibiting glycolysis was shown to overcome taxol-resistance in colorectal cancer cells [130].